We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Halts Development of Osteoporosis Therapy Due to Increased Stroke Risks
Merck Halts Development of Osteoporosis Therapy Due to Increased Stroke Risks
Merck is suspending development of its osteoporosis candidate after an analysis of its Phase III fracture outcomes study demonstrated that the therapy increases the risk of strokes.